Meng, Y., et al
Cardiovascular outcome studies have shown cardiovascular advantages associated with certain GLP-1 receptor agonists, especially in those with pre-existing cardiovascular illness
Mientras el GLP-1 acta sobre apetito, vaciamiento gstrico e insulina, el GIP regula la grasa corporal y la respuesta metablica, disminuyendo el almacenamiento de grasa visceral alrededor de los rganos
While ertugliflozin did not outperform placebo for MACE, it significantly reduced hospitalizations for HF by 30% ( The SCORED clinical study, which included 10,584 patients with T2DM and an estimated glomerular filtration rate (eGFR) of 2560 ml/m/1.73 m, evaluated the effects of sotagliflozin on cardiovascular death and hospitalization for HF
Midlife women face extra challenges with perimenopause and menopausewhere declining estrogen directly accelerates weight gain, body composition changes with visceral fat around the belly, and rising insulin resistanceall things that GLP-1s can help address
The medical providers at Center for Aesthetic Medicine follow the micro dose approach for their longevity patients ensuring they receive the longevity benefits while maintaining their quality of life
